<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572880</url>
  </required_header>
  <id_info>
    <org_study_id>1234567</org_study_id>
    <nct_id>NCT04572880</nct_id>
  </id_info>
  <brief_title>Evaluation of Minimal Invasive Glaucoma Surgery</brief_title>
  <official_title>Evaluation of Minimal Invasive Glaucoma Surgery: Trabeculectomy vs. XEN ® vs. Preserflo ®. Randomized Clinial Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is a neurodegenerative disease with an accelerated and progressiv retinal ganglion&#xD;
      cell loss and concomitant visual field defects. Glaucoma can be treated with eye drops, laser&#xD;
      therapy or surgery. Various surgical approaches to lower intraocular pressure are available,&#xD;
      amongst which trabeculectomy is the gold standard. Recently minimal invasive glaucoma surgery&#xD;
      has been introduced and has become a good alternative to trabeculectomy. Randomized clinical&#xD;
      trials investigating the postoperative outcomes of various types of glaucoma surgery are&#xD;
      limited.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      150 Patients will be randomized to one of the 3 surgeries. Trabeculectomy Preserflo® or Xen®&#xD;
      will be done according to a standard protocol Data will be collected for 5 years after&#xD;
      surgery, Visual Acuity, Applanation Tonometry, Slit lamp Biomicroscopy, Endothelial cell&#xD;
      cound, visual fields, optical coherence tomography of the optic disc, retina and anterior&#xD;
      segment, impression cytology and life quality will be done on day of enrollment and during&#xD;
      followup. Mean Intraocular pressure and number of glaucoma medications, Endothelial cell&#xD;
      loss, visual acuity, visual fields and assessment of life quality will be assessed during the&#xD;
      post-operative follow-ups at one week, one month, 3 months, 6 months, 9 months, 1 year, 2&#xD;
      years, 3 years, 4 years and 5 years after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean intraocular pressure</measure>
    <time_frame>up to 5 years post surgery</time_frame>
    <description>Goldmann Applanation Tonometry [mmHg]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of medications</measure>
    <time_frame>up to 5 years post surgery</time_frame>
    <description>antihypertensive eye-drops</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Trabeculectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>XEN®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Preserflo®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy</intervention_name>
    <description>Trabeculectomy is performed</description>
    <arm_group_label>Trabeculectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XEN®</intervention_name>
    <description>Microinvasive Surgery with XEN® is performed</description>
    <arm_group_label>XEN®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Preserflo®</intervention_name>
    <description>Microinvasive Surgery with Preserflo® is performed</description>
    <arm_group_label>Preserflo®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patiens with glaucoma in which surgery is indicated to reach target intraocular&#xD;
             pressure&#xD;
&#xD;
          -  Subjects not anticipated to require any further surgery in the next 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not want to make follow-ups at the department&#xD;
&#xD;
          -  angle closure, uveitic, neovascular, congenital glaucoma, iridocorneal endothelial&#xD;
             syndrom, Axenfeld-Rieger syndrom.&#xD;
&#xD;
          -  Prior filtering glaucoma surgery, suprachoroidal stent, retinal surgery, corneal graft&#xD;
             surgery or cyclophotocoagulation&#xD;
&#xD;
          -  Any major ocular inflammation up to 30 days prior to surgery&#xD;
&#xD;
          -  Conjunctival scarring&#xD;
&#xD;
          -  Allergy to any drugs required for the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Lindner Ewald, MD</investigator_full_name>
    <investigator_title>Priv.-Doz. Dr.med.univ. Lindner Ewald</investigator_title>
  </responsible_party>
  <keyword>MIGS</keyword>
  <keyword>XEN®</keyword>
  <keyword>Trabeculectomy</keyword>
  <keyword>Preserflo®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

